Inactive Instrument

Other languages Ventrus Biosciences Inc Nasdaq

Equities

US9228221019

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-08	Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-28	Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08
Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	01-19
Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024	01-04
Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board	12-07
Assembly Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer	11-08
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	17/10/23
Sector Update: Health Care	17/10/23
Gilead Sciences, Assembly Biosciences Working Together to Accelerate Development of New Antiviral Therapies	17/10/23
Gilead Sciences, Inc. and Assembly Biosciences, Inc. Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases	17/10/23
Assembly Biosciences Nominates Development Candidate Abi-6250, an Orally Bio Available HDV Entry Inhibitor	02/10/23
Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting	19/09/23
Assembly Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Assembly Biosciences, Inc. Presents New Data Highlighting Herpes Simplex Virus Development Candidate Abi-5366 At the 47Th Annual International Herpesvirus Workshop	17/07/23
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23
Assembly Biosciences Announces Additional Promising Data from Phase 1A Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate Abi-4334 and Provides Pipeline Update	18/04/23
Assembly Biosciences Files $150 Million Mixed Shelf	23/03/23
Assembly Biosciences, Inc. Provides Update on its Core Inhibitor Pipeline	22/03/23
Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes	15/02/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ventrus Biosciences Inc Nasdaq

Equities

US9228221019

Other languages

Filters